Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
26. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
27. |
ECCT/19/03/01 | Validation of syringe extension device Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures |
Principal Investigator(s) 1. Stephen Gwer 2. Aparna Ramanathan Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kisumu County Hospital (Kisumu county) 3. God\'s Will Clinic (Kisumu county) 4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county) |
View |
28. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |
29. |
ECCT/18/06/01 | Safety, Acceptability, and Feasibility of enterade® (SAFE) Safety, Acceptability, and Feasibility of enterade® in children at risk for environmental enteric dysfunction in Kakamega County, Kenya |
Principal Investigator(s) 1. Michael Benjamin Arndt 2. James Mukabi Site(s) in Kenya Kakamega County General Hospital (CGH) |
View |
30. |
ECCT/17/08/05 | Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection. |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho |
View |